---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-135212"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:44:41.762685+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics reports interim Phase 1 data for PRT2527; plans to partner CDK9 program

## Summary
- PRT2527 monotherapy ORR 17.4% (4/23 evaluable); combination with zanubrutinib ORR 38.5% (5/13 evaluable).
- CRs observed in DLBCL (monotherapy and combo) and MCL (combo); responses in patients with prior CAR-T therapy.
- Most common TEAE: neutropenia (48%, grade≥3: 46%); one DLT of tumor lysis syndrome at 24 mg/m2 dose.
- Prelude will seek a partner for PRT2527 to focus resources on SMARCA degrader programs.
- Data presented at 66th ASH Annual Meeting on Dec 11, 2024; 46 patients safety-evaluable as of Sep 17, 2024.

## SEC filing metadata
- accession: 0000950170-24-135212
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024135212/0000950170-24-135212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024135212/prld-20241211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-135212
- JSON: https://secwatch.observer/filing/0000950170-24-135212.json
- Plain text: https://secwatch.observer/filing/0000950170-24-135212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.